New Age Alpha Advisors LLC Makes New $7.86 Million Investment in Insulet Co. (NASDAQ:PODD)

New Age Alpha Advisors LLC bought a new stake in shares of Insulet Co. (NASDAQ:PODD) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund bought 30,096 shares of the medical instruments supplier’s stock, valued at approximately $7,857,000.

Several other large investors have also recently bought and sold shares of PODD. SBI Securities Co. Ltd. bought a new position in shares of Insulet during the 4th quarter worth approximately $36,000. Sumitomo Mitsui DS Asset Management Company Ltd lifted its holdings in shares of Insulet by 30.1% during the fourth quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 8,395 shares of the medical instruments supplier’s stock worth $2,192,000 after buying an additional 1,942 shares in the last quarter. Orion Portfolio Solutions LLC grew its position in shares of Insulet by 86.2% during the 3rd quarter. Orion Portfolio Solutions LLC now owns 7,826 shares of the medical instruments supplier’s stock worth $1,822,000 after purchasing an additional 3,623 shares in the last quarter. Nomura Asset Management Co. Ltd. grew its position in Insulet by 5.7% during the third quarter. Nomura Asset Management Co. Ltd. now owns 153,416 shares of the medical instruments supplier’s stock worth $35,708,000 after buying an additional 8,301 shares in the last quarter. Finally, Stifel Financial Corp increased its position in shares of Insulet by 2.8% in the third quarter. Stifel Financial Corp now owns 10,527 shares of the medical instruments supplier’s stock worth $2,450,000 after purchasing an additional 290 shares during the period.

Wall Street Analysts Forecast Growth

PODD has been the subject of several analyst reports. JPMorgan Chase & Co. raised their price target on shares of Insulet from $280.00 to $330.00 and gave the company an “overweight” rating in a research note on Thursday, December 12th. StockNews.com downgraded Insulet from a “buy” rating to a “hold” rating in a report on Tuesday, March 4th. Wells Fargo & Company increased their price target on shares of Insulet from $305.00 to $322.00 and gave the company an “overweight” rating in a research report on Friday, February 21st. Stifel Nicolaus increased their price target on Insulet from $245.00 to $293.00 and gave the stock a “hold” rating in a research note on Friday, February 21st. Finally, Citigroup boosted their target price on shares of Insulet from $310.00 to $355.00 and gave the company a “buy” rating in a report on Friday, February 21st. Four investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. Based on data from MarketBeat, Insulet has a consensus rating of “Moderate Buy” and a consensus target price of $292.06.

Insiders Place Their Bets

In related news, Director Wayne A.I. Frederick sold 1,825 shares of the business’s stock in a transaction that occurred on Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total transaction of $501,875.00. Following the completion of the sale, the director now directly owns 3,231 shares in the company, valued at approximately $888,525. The trade was a 36.10 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Eric Benjamin sold 12,394 shares of the firm’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total value of $3,470,320.00. Following the sale, the executive vice president now directly owns 11,383 shares in the company, valued at approximately $3,187,240. This represents a 52.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.47% of the company’s stock.

Insulet Trading Down 1.7 %

Shares of NASDAQ PODD opened at $260.27 on Friday. Insulet Co. has a 1 year low of $160.19 and a 1 year high of $289.46. The firm has a 50-day moving average of $272.03 and a 200 day moving average of $258.25. The stock has a market cap of $18.28 billion, a P/E ratio of 44.95, a price-to-earnings-growth ratio of 3.62 and a beta of 1.29. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.00 by $0.15. The company had revenue of $597.50 million for the quarter, compared to the consensus estimate of $582.02 million. Insulet had a return on equity of 24.46% and a net margin of 20.19%. As a group, sell-side analysts expect that Insulet Co. will post 3.92 EPS for the current fiscal year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.